Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.

ABSTRACT: Acute myeloid leukemia (AML) is a biologically complex and molecularly and clinically heterogeneous disease, and its incidence increases with age. Cytogenetics and mutation testing remain important prognostic tools for treatment after induction therapy. The post-induction treatment is dependent on risk stratification. Despite rapid advances in determination of gene mutations involved in the pathophysiology and biology of AML, and the rapid development of new drugs, treatment improvements changed slowly over the past 30 years, with the majority of patients eventually experiencing relapse and dying of their disease. Allogenic hematopoietic stem cell transplantation remains the best chance of cure for patients with intermediate- or high-risk disease. This review gives an overview about advanc

SUBMITTER: Medinger M 

PROVIDER: S-EPMC5070622 | biostudies-literature | 2016 09-10

REPOSITORIES: biostudies-literature